2023 - Cancer Currents Blog
-
For the first time in decades, people with advanced bladder cancer have more effective treatment options. New clinical trial results mark a pivotal moment following years of little progress, bladder cancer experts believe.
-
A new study shows that, in some tumors, a subset of cancer cells can drain mitochondria, the tiny structures within cells that produce energy, from T cells and use them for their own energy needs.
-
FDA has changed its 2021 approval of pembrolizumab (Keytruda) along with trastuzumab (Herceptin) and chemotherapy for treating HER2-positive stomach or GEJ cancer. The agency also announced a new approval of pembrolizumab for HER2-negative forms of these same cancers.
-
For people with lung cancer and medullary thyroid cancer whose tumors have changes in the RET gene, selpercatinib improved progression-free survival compared with other common treatments, according to new clinical trial results.
-
A new study, conducted largely in mice, may help explain why a currently used molecular marker—called mismatch repair deficiency—doesn’t always work to predict which patients will respond to immunotherapies called immune checkpoint inhibitors.
-
The Food and Drug Administration (FDA) for the first time has granted marketing authorization for a blood test, the Invitae Common Hereditary Cancers Panel. The test detects inherited genetic changes that increase the risk of developing certain cancers.